Sierra Oncology, Inc.
Sierra Oncology, Inc. (SRRA): 2 pipeline candidates · ~32 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
32.1 months
D/E 0.07 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Sierra Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$274.3M
Quarterly Burn
$25.7M
Runway
32.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| momelotinib | Phase 3 |
| sra737 | Preclinical |
Frequently asked questions
How many drug candidates are in Sierra Oncology, Inc.'s pipeline?
Sierra Oncology, Inc. (SRRA) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sierra Oncology, Inc.'s lead drug candidate?
Sierra Oncology, Inc.'s most advanced tracked candidate is momelotinib (Phase 3) for myelofibrosis.
What is Sierra Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sierra Oncology, Inc. has approximately 32.1 months of cash runway.
Who is the CEO of Sierra Oncology, Inc.?
Stephen G. Dilly is the chief executive officer of Sierra Oncology, Inc. (SRRA).
Get the full picture on Sierra Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.